Skip to main content
Premium Trial:

Request an Annual Quote

NIH Awards Omicia, Johns Hopkins $187,000 to Study Genetics of Cardiovascular Disease

NEW YORK (GenomeWeb News) - Omicia said today it has received a small business technology transfer grant worth $187,700 from the National Institutes of Health to support a collaboration with Johns Hopkins University to study the genetic underpinnings of cardiovascular disease.
The award from the National Heart, Lung, and Blood Institute will support a project conducted by Omicia and JHU biomedical engineering researcher Joel Bader that aims to identify genetic risk factors for cardiovascular disease "by drawing parallels from systematic genetic screens performed on fruit flies and other model organisms," the company said.
These screens will be used to determine phenotypes for relevant genes in each of the model organisms.
The collaborators will also develop data-mining algorithms that will help select sets of genes that lead to similar phenotypes in different organisms and which are likely to play significant roles in human health and disease, Omicia said.
Bader said in a statement that the collaborators "aim to significantly advance the understanding of the genetic basis of cardiovascular disease, paving the way towards the earliest possible diagnosis and the most appropriate therapeutic options."

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.